Cholecystokinin-8 increases Fos-like immunoreactivity in myenteric neurons of the duodenum and jejunum more after intraperitoneal than after intravenous injection.
The objective of this study was to measure the relative efficacy and potency of cholecystokinin-8 (CCK-8) given by intraperitoneal (i.p.) and intravenous (i.v.) injection to stimulate Fos-like immunoreactivity (Fos-LI) in neurons of the myenteric plexus in the duodenum and jejunum. The subjects for his experiment were 40 male Sprague-Dawley rats divided into eight treatment groups (n=5 rats per treatment). Four groups of rats were injected with 5, 10, and 40 microg/kg sulfated CCK-8 and saline (control) i.p., and the remaining groups with the same treatments i.v. We then detected Fos-LI, a marker for neuronal activation, in the myenteric plexus of the duodenum and jejunum, in response to the previous doses and routes. All of the CCK-8 doses administered by both routes increased Fos-LI in the myenteric plexus of the duodenum and jejunum significantly more than saline did. Although both routes were efficacious in increasing Fos-LI, CCK-8 i.p. was significantly more potent than CCK-8 i.v. These data provide immunohistochemical evidence that i.p. administration of CCK-8 is a more potent stimulant of Fos-LI in the neurons of the myenteric plexus of the duodenum and jejunum than i.v. injection.
Webb
Tennille
T
Gastroenterology Laboratory, Department of Biomedical Sciences, College of Veterinary Medicine, Tuskegee University, Tuskegee, AL 36088, USA.
Gulley
Stephen
S
Pruitt
Fleurette
F
Esdaile
Alton R
AR
Sharma
Sanjay K
SK
Cox
James E
JE
Smith
Gerard P
GP
Sayegh
Ayman I
AI
D000818:Animals; D002766:Cholecystokinin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004386:Duodenum / Q000187:drug effects / Q000276:immunology*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007583:Jejunum / Q000187:drug effects / Q000276:immunology*; D008297:Male; D009197:Myenteric Plexus / Q000187:drug effects / Q000276:immunology*; D009474:Neurons / Q000187:drug effects / Q000276:immunology*; D010446:Peptide Fragments / Q000008:administration & dosage*; D016760:Proto-Oncogene Proteins c-fos / Q000276:immunology*; D051381:Rats; D017207:Rats, Sprague-Dawley
D010446:Peptide Fragments; D016760:Proto-Oncogene Proteins c-fos; C410885:cholecystokinin 8; D002766:Cholecystokinin